{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:16:31Z","timestamp":1775175391591,"version":"3.50.1"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Neoadjuvant therapy (NAT) followed by surgery is becoming a standard treatment even for resectable pancreatic cancer (RPC). However, it is unclear whether NAT is necessary for all RPC cases.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A total of 296 patients diagnosed with RPC and under 80 years old were retrospectively analyzed, focusing on tumor markers (TMs). The cutoff value of TM was decided based on the classification by the International Association of Pancreatology.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Among 80 cases who underwent NAT, 72 cases accomplished surgical resection. Upfront surgery (UpS) was planned in 216 cases, and surgical resection was accomplished in 199 cases. Resection rate showed no difference between the two groups (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.638). Although NAT group showed a favorable trend in overall survival (OS) compared with the UpS group, the difference was not significant (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.143). carbohydrate antigen 19-9 &gt;500\u00a0U\/mL and\/or duke pancreatic monoclonal antigen type 2 &gt;700\u00a0U\/mL was defined as high TM. When comparing in TM-high group (n = 83), patients with NAT showed significantly better OS than those without NAT (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.024). In TM-low group (n = 213), the OS curves completely overlapped with no difference (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.902). A multivariate analysis demonstrated that undergoing NAT was the sole independent prognostic factor in the TM-high group (hazard ratio: 0.48, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.044) while undergoing NAT was not a prognostic factor in the TM-low group.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>The efficacy of NAT for RPC might be limited to the subset of patients with high TM.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mpa.0000000000002485","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T11:03:34Z","timestamp":1740740614000},"page":"e630-e636","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy of Neoadjuvant Therapy for Resectable Pancreatic Cancer Might be Limited to Biologically Borderline Resectable Cases"],"prefix":"10.1097","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2203-256X","authenticated-orcid":false,"given":"Yoshiyasu","family":"Kato","sequence":"first","affiliation":[{"name":"Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Ashida","sequence":"additional","affiliation":[{"name":"Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuhisa","family":"Ohgi","sequence":"additional","affiliation":[{"name":"Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shimpei","family":"Otsuka","sequence":"additional","affiliation":[{"name":"Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyuki","family":"Dei","sequence":"additional","affiliation":[{"name":"Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuhiko","family":"Uesaka","sequence":"additional","affiliation":[{"name":"Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Yamazaki","sequence":"additional","affiliation":[{"name":"Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teiichi","family":"Sugiura","sequence":"additional","affiliation":[{"name":"Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,8]]},"reference":[{"key":"R1-20250711","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020 Accessed July 29, 2024","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"R3-20250711","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1097\/SLA.0000000000002234","article-title":"Patterns, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma","volume":"267","author":"Groot","year":"2018","journal-title":"Ann Surg"},{"key":"R4-20250711","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/SLA.0000000000006142","article-title":"Progression of site-specific recurrence of pancreatic cancer and implications for treatment","volume":"280","author":"Rompen","year":"2024","journal-title":"Ann Surg"},{"key":"R5-20250711","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1200\/JCO.2019.37.4_suppl.189","article-title":"Randomized phase II\/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02\/JSAP-05)","volume":"37","author":"Unno","year":"2019","journal-title":"J Clin Oncol"},{"key":"R7-20250711","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1200\/JCO.21.02233","article-title":"Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC trial","volume":"40","author":"Versteijne","year":"2022","journal-title":"J Clin Oncol"},{"key":"R8-20250711","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S2468-1253(22)00348-X","article-title":"Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, folfirinox, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial","volume":"8","author":"Ghaneh","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R9-20250711","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1007\/s11605-015-2890-4","article-title":"Neoadjuvant chemoradiotherapy and surgery versus surgery alone in resectable pancreatic cancer: a single-center prospective, randomized, controlled trial which failed to achieve accrual targets","volume":"19","author":"Casadei","year":"2015","journal-title":"J Gastrointest Surg"},{"key":"R10-20250711","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00066-014-0737-7","article-title":"Neoadjuvant chemoradiation therapy with gemcitabine\/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial","volume":"191","author":"Golcher","year":"2015","journal-title":"Strahlenther Onkol"},{"key":"R11-20250711","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/jhbp.1302","article-title":"Role of neoadjuvant treatment in resectable pancreatic cancer according to vessel invasion and increase of CA19-9 levels","volume":"30","author":"Kim","year":"2023","journal-title":"J Hepato-Bil Pancreat Sci"},{"key":"R12-20250711","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.pan.2024.03.012","article-title":"Reconsideration of the clinical impact of neoadjuvant therapy in resectable and borderline resectable pancreatic cancer: a dual-institution collaborative clinical study","volume":"24","author":"Yamada","year":"2024","journal-title":"Pancreatology"},{"key":"R13-20250711","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.hpb.2019.01.012","article-title":"Biological and conditional factors should be included when defining criteria for resectability for patients with pancreatic cancer","volume":"21","author":"Kato","year":"2019","journal-title":"HPB"},{"key":"R14-20250711","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/jhbp.1049","article-title":"New criteria of resectability for pancreatic cancer: a position paper by the Japanese Society of Hepato-Biliary-Pancreatic Surgery (JSHBPS)","volume":"29","author":"Oba","year":"2022","journal-title":"J Hepatobil Pancreat Sci"},{"key":"R15-20250711","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.pan.2017.11.011","article-title":"International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017","volume":"18","author":"Isaji","year":"2018","journal-title":"Pancreatology"},{"key":"R16-20250711","doi-asserted-by":"crossref","first-page":"4992","DOI":"10.1245\/s10434-022-11628-8","article-title":"The association between neoadjuvant therapy and pathological outcomes in pancreatic cancer patients after resection: prognostic significance of microscopic venous invasion","volume":"29","author":"Kubo","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"R17-20250711","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/MPA.0b013e3182550d77","article-title":"Utility of contrast-enhanced FDG-PET\/CT in the clinical management of pancreatic cancer: Impact on diagnosis, staging, evaluation of treatment response, and detection of recurrence","volume":"42","author":"Asagi","year":"2013","journal-title":"Pancreas"},{"key":"R18-20250711","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00423-023-02906-4","article-title":"Long-term adjuvant chemotherapy after resection for pancreatic cancer patients with positive peritoneal lavage cytology","volume":"408","author":"Ohgi","year":"2023","journal-title":"Langenbecks Arch Surg"},{"key":"R19-20250711","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0140-6736(16)30583-9","article-title":"Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)","volume":"388","author":"Uesaka","year":"2016","journal-title":"Lancet"},{"key":"R20-20250711","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"R21-20250711","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/COC.0b013e318280d5f0","article-title":"CA 19\u20139 nonproduction is associated with poor survival after resection of pancreatic adenocarcinoma","volume":"37","author":"Hayman","year":"2014","journal-title":"Am J Clin Oncol"},{"key":"R22-20250711","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.pan.2018.08.003","article-title":"New observations on the utility of CA19-9 as a biomarker in Lewis negative patients with pancreatic cancer","volume":"18","author":"Luo","year":"2018","journal-title":"Pancreatology"},{"key":"R23-20250711","doi-asserted-by":"crossref","first-page":"e1278","DOI":"10.1097\/SLA.0000000000005395","article-title":"Serum DUPAN-2 could be an alternative biological marker for CA19-9 nonsecretors with pancreatic cancer","volume":"277","author":"Omiya","year":"2023","journal-title":"Ann Surg"},{"key":"R24-20250711","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/ags3.12629","article-title":"Importance of triple tumor markers as biomarkers in patients with pancreatic ductal adenocarcinoma","volume":"7","author":"Takagi","year":"2023","journal-title":"Ann Gastroenterol Surg"},{"key":"R25-20250711","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1245\/s10434-024-14945-2","article-title":"Prognostic significance of biologic factors in patients with a modest radiologic response to neoadjuvant treatment for resectable and borderline resectable pancreatic cancers: impact of the combination index of sialyl-Lewis antigen-related tumor markers","volume":"31","author":"Miyahara","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"R26-20250711","doi-asserted-by":"crossref","first-page":"5792","DOI":"10.1245\/s10434-023-13564-7","article-title":"Prognostic role of preoperative duke pancreatic monoclonal antigen type 2 levels in patients with pancreatic cancer","volume":"30","author":"Shimizu","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"R27-20250711","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jss.2019.01.061","article-title":"The impact of tumor location on resection and survival for pancreatic ductal adenocarcinoma","volume":"239","author":"Winer","year":"2019","journal-title":"J Surg Res"},{"key":"R28-20250711","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.3892\/etm.2021.10574","article-title":"Clinical prognostic value of circulating tumor cells in the treatment of pancreatic cancer with gemcitabine chemotherapy","volume":"22","author":"Wang","year":"2021","journal-title":"Exp Ther Med"},{"key":"R29-20250711","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1002\/jhbp.1353","article-title":"Randomized phase II trial of chemoradiotherapy with S-1 versus combination chemotherapy with gemcitabine and S-1 as neoadjuvant treatment for resectable pancreatic cancer (JASPAC 04)","volume":"30","author":"Sugiura","year":"2023","journal-title":"J Hepato-Bil Pancreat Sci"}],"container-title":["Pancreas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPA.0000000000002485","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T20:00:16Z","timestamp":1752264016000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPA.0000000000002485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,3]]},"references-count":27,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/mpa.0000000000002485","relation":{},"ISSN":["1536-4828"],"issn-type":[{"value":"1536-4828","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,3]]},"assertion":[{"value":"2024-11-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}